Novo Nordisk achieves historic breakthrough with first GLP-1 pill

The US Food and Drug Administration (FDA) has approved the first GLP-1 pill for the treatment of obesity. This product was developed by Novo Nordisk, the manufacturer of the blockbuster medication Wegovy. The decision is considered a milestone for the rapidly growing weight loss drug market, as it creates an effective oral alternative to the currently dominant injections, potentially opening up new patient groups. Market launch set for early 2026 with aggressive pricing strategy Novo Nordisk plans a broad market launch of the pill in early 2026....